Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence

Introduction  Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence  F. Cantini, D. Goletti .......................................................... 1

Update on the Epidemiology of Tuberculosis in Italy  M. Conversano .......................................................... 4

The Spectrum of Tuberculosis Infection: New Perspectives in the Era of Biologics  G. Delogu, D. Goletti .......................................................... 11

Cellular and Humoral Immune Responses During Tuberculosis Infection: Useful Knowledge in the Era of Biological Agents  A. Matucci, E. Maggi, A. Vultaggio .......................................................... 17

Performance of the Tuberculin Skin Test and Interferon-γ Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches  D. Goletti, A. Sanduzzi, G. Delogu .......................................................... 24

Diagnostic Accuracy of Chest Radiography for the Diagnosis of Tuberculosis (TB) and Its Role in the Detection of Latent TB Infection: a Systematic Review  R. Piccazzo, F. Paparo, G. Garlaschi .......................................................... 32

Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International Recommendations  F. Iannone, F. Cantini, G. Lapadula .......................................................... 41

Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance  F. Cantini, L. Niccoli, D. Goletti .......................................................... 47

Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor-α (TNF-α) Targeted Biologics and Recently Licensed TNF-α Inhibitors: Data from Clinical Trials and National Registries  F. Cantini, L. Niccoli, D. Goletti .......................................................... 56

Tuberculosis Reactivation Risk in Dermatology  L. Pescitelli, F. Ricceri, F. Prignano .......................................................... 65

Current Treatment Options for Latent Tuberculosis Infection  M. Bocchino, A. Matarese, A. Sanduzzi .......................................................... 71

Restarting Biologics and Management of Patients with Flares of Inflammatory Rheumatic Disorders or Psoriasis During Active Tuberculosis Treatment  F. Cantini, F. Prignano, D. Goletti .......................................................... 78

Cost for Tuberculosis Care in Developed Countries: Which Data for an Economic Evaluation?  L. Trieste, G. Turchetti .......................................................... 83